Cargando…

Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimi, Ryusuke, Ishigatsubo, Yoshiaki, Ozato, Keiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373075/
https://www.ncbi.nlm.nih.gov/pubmed/22701487
http://dx.doi.org/10.1155/2012/718237
_version_ 1782235404558139392
author Yoshimi, Ryusuke
Ishigatsubo, Yoshiaki
Ozato, Keiko
author_facet Yoshimi, Ryusuke
Ishigatsubo, Yoshiaki
Ozato, Keiko
author_sort Yoshimi, Ryusuke
collection PubMed
description Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines. In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE.
format Online
Article
Text
id pubmed-3373075
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33730752012-06-14 Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus Yoshimi, Ryusuke Ishigatsubo, Yoshiaki Ozato, Keiko Int J Rheumatol Review Article Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines. In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE. Hindawi Publishing Corporation 2012 2012-06-04 /pmc/articles/PMC3373075/ /pubmed/22701487 http://dx.doi.org/10.1155/2012/718237 Text en Copyright © 2012 Ryusuke Yoshimi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Yoshimi, Ryusuke
Ishigatsubo, Yoshiaki
Ozato, Keiko
Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
title Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
title_full Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
title_fullStr Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
title_full_unstemmed Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
title_short Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
title_sort autoantigen trim21/ro52 as a possible target for treatment of systemic lupus erythematosus
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373075/
https://www.ncbi.nlm.nih.gov/pubmed/22701487
http://dx.doi.org/10.1155/2012/718237
work_keys_str_mv AT yoshimiryusuke autoantigentrim21ro52asapossibletargetfortreatmentofsystemiclupuserythematosus
AT ishigatsuboyoshiaki autoantigentrim21ro52asapossibletargetfortreatmentofsystemiclupuserythematosus
AT ozatokeiko autoantigentrim21ro52asapossibletargetfortreatmentofsystemiclupuserythematosus